Crispr Earnings: Commercial Launch of Casgevy Is Underway; Positive Outlook and Shares Undervalued

Crispr Therapeutics’ first-quarter results align with our expectations, and its early-stage pipeline candidates are advancing in clinical trials. We continue to expect 2024 will be a pivotal year as Crispr rolls out global commercialization efforts for its recently approved gene therapy, Casgevy, for the treatment of both sickle cell disease and transfusion-dependent beta thalassemia. We think Casgevy could hold strong pricing power and become a blockbuster drug, generating over $1 billion in revenue by 2026 for Crispr, pending a successful commercial launch.